Matthew Caufield

Stock Analyst at HC Wainwright & Co.

(0)
# 5096
Out of 5,356 analysts
157
Total ratings
23.64%
Success rate
-36.55%
Average return
25 Stocks
Name Action PT Current % Upside Ratings Updated
AKBA Akebia Therapeutics
Assumes: Buy
8
3.69 116.8% 1 Jun 4, 2025
DMAC DiaMedica Therapeuti...
Reiterates: Buy
10 10
4.09 144.5% 5 May 29, 2025
UBX Unity Biotechnology
Downgrades: Neutral
4 2
0.69 189.86% 9 May 27, 2025
TARS Tarsus Pharmaceutica...
Assumes: Buy
72
44.03 63.52% 1 May 27, 2025
OPTN OptiNose
Reiterates: Neutral
9 9
n/a n/a 8 May 19, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
10 10
2.45 308.16% 13 May 19, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
30 30
9.65 210.88% 3 May 16, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
30 30
2.41 1144.81% 6 May 15, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
42 42
15.69 167.69% 8 May 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
32 32
8.47 277.8% 3 May 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
38 38
30.28 25.5% 5 May 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
28 20
4.7 325.53% 9 May 2, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
10 10
0.77 1198.7% 4 May 1, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
12 12
0.83 1345.78% 4 Apr 1, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
8 8
1.02 684.31% 3 Apr 1, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
2 2
1.96 2.04% 6 Mar 31, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
3 3
3.95 -24.05% 4 Mar 31, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
12 2
n/a n/a 7 Mar 25, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
2 2
3.17 -36.91% 16 Mar 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
100 100
25.22 296.51% 7 Mar 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
36 36
3.88 827.84% 18 Mar 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
20 18
n/a n/a 9 Aug 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
28
237.25 -88.2% 1 Aug 22, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
35 40
n/a n/a 6 May 2, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
20
n/a n/a 1 Jul 18, 2022